Daniel Barenboim, Parkinson's disease
Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...
Onapgo is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in patients with advanced disease ...
The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...
Richard Balanson says when one suffers a disease "you begin to accumulate friends" who have their own story with the same ...
A Huntsville-based biotechnology company has secured $10 million in funding to begin the trial of a new way to deliver medication to advanced Parkinson’s disease patients.
The Google cofounder has donated more than $1.5 billion to Parkinson’s research. Now, as he takes on autism, he’s also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback